CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 25 target
Drug / intervention
SNS-032 Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00292864
NCT00292864Phase 1Completed
CompareCT.gov

Phase 1 Open-Label, Multicenter, Dose-Escalation Clinical Study of the Safety and Tolerability of SNS-032, a Novel Cyclin-Dependent Kinase Inhibitor, Administered to Patients With Select Advanced Solid Tumors

Sunesis Pharmaceuticals·interventional·Posted Feb 16, 2006·Updated Jun 7, 2012

In Brief

A Phase 1 clinical trial evaluating SNS-032 Injection for Tumors. Completed, enrolled 25 participants across 6 sites.

Detailed Summary

The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 16, 2006
Enrollment StartJan 1, 2006
Study CompletionDec 1, 2007
TodayJul 2, 2026
Posted 20.4 years ago

Interventions

SNS-032 Injectiondrug